J&J: presents final analysis of Griffin study

(CercleFinance.com) - The Janssen Pharmaceutical Companies of Johnson & Johnson has presented the final analysis of the Phase 2 GRIFFIN study for the investigational quadruplet regimen of DARZALEX (daratumumab) in patients with newly diagnosed, transplant-eligible multiple myeloma.


The data was presented at the plenary session of the International Myeloma Society (IMS) annual meeting.

The final analysis of the GRIFFIN trial highlights the potential benefit of adding daratumumab to RVR for the treatment of newly diagnosed, transplant-eligible patients, the GRIFFIN trial director said.

J&J shares have started trading down slightly today.



Copyright (c) 2022 CercleFinance.com. All rights reserved.